Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences

        Print
| Source: Sucampo Pharmaceuticals, Inc.

BETHESDA, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be presented at the American Pain Society ("APS") Conference in Tampa, Florida and Digestive Disease Week ("DDW") 2014 in Chicago, Illinois. The information regarding both presentations can be found below.

The following poster will be presented at APS on Friday, May 2, 2014 from 8:45 AM to 10:15 AM ET at the Tampa Convention Center:

  • Efficacy of lubiprostone for the treatment of opioid-induced constipation according to opioid class (Webster et al.) Poster 452. (Randall P. Brewer, MD, Shadreck Mareya, PhD, Anca Popescu, MD, Lynn R. Webster, MD)

The following posters will be presented at DDW on Saturday, May 3, 2014 between 12:00 PM to 2:00 PM CT in the South Hall of McCormick Place convention center in Chicago, Illinois:

  • Lubiprostone for Treatment of Opioid-Induced Constipation: Analysis of Response by Opioid Class (M. Mazen Jamal, MD, MPH, Byron Cryer, MD, FACG, Taryn Losch-Beridon - Poster # Sa2020) 
     
  • A Pooled Analysis of Response to Lubiprostone in Patients With Opioid-Induced Constipation Receiving Non-Methadone Opioids Versus Methadone  (Egilius L. H. Spierings, MD, PhD, Douglas A. Drossman, MD, MACG, Byron Cryer, MD, FACG, Taryn Losch-Beridon  - Poster # Sa2036) 
     
  • Nausea Reported by Patients Enrolled in Clinical Studies of Lubiprostone: Analysis of Well-Controlled and Long-Term, Open-Label Studies of Chronic Idiopathic Constipation, Opioid-Induced Constipation, and Irritable Bowel Syndrome With Constipation (Byron Cryer, MD, FACG, Lynn R. Webster, MD, Taryn Losch-Beridon - Poster # Sa2021) 
     
  • The CIC-2 chloride channel activator, lubiprostone, prevents ileal epithelial permeability alterations in a murine model of diarrhea-predominant irritable bowel syndrome (Muriel Larauche, PhD, Yvette Taché, PhD, Ganna Toltstanova, PhD, Pu-Qing Yuan, PhD)

The following poster will be presented at DDW during the Basic Late Breaking Abstract Poster Session on Tuesday, May 6, 2014 between 12:00 PM to 2:00 PM CT in the South Hall of McCormick Place convention center in Chicago, Illinois:

  • Lubiprostone Reduces Murine Colitis Principally in a ClC-2-Dependent Manner (Anthony T. Blikslager, PhD, Younggeon Jin, Tiffany A. Pridgen – Poster # Tu2028)

About lubiprostone

Lubiprostone is a member of a class of compounds called prostones that directly activates ClC-2 chloride channels located in the apical membrane of the human intestinal epithelial cells. This activation causes an increase in chloride ions (Cl-) and intestinal fluid secretion into the lumen, thereby promoting the motility of the gastrointestinal (GI) tract contents.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs based on ion channel activators known as prostones. Prostones are naturally occurring fatty acid metabolites with unique physiological activities. Sucampo has two marketed products – AMITIZA and RESCULA® – and a pipeline of prostone-based product candidates in clinical development. A global company, Sucampo is headquartered in Bethesda, Maryland, and has operations in Japan, the United Kingdom and Switzerland. For more information, please visit www.sucampo.com.

The Sucampo logo is the registered trademark and the tagline, The Science of Innovation, is a pending trademark of Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference.

Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations
and Corporate Communications
1-240-223-3718